Pfizer (PFE)

Executive Summary

Pfizer Inc. (NYSE: PFE) is a global biopharmaceutical leader with a market capitalization of approximately $155.8 billion. Following a significant surge in revenue from its COVID-19 vaccine (Comirnaty) and oral antiviral (Paxlovid), the company has faced a steep revenue decline as pandemic demand waned. To offset this, Pfizer is focusing on its deep pipeline of over 90 programs across oncology, vaccines, inflammation, and rare diseases. Key growth drivers include new product launches such as Prevnar 20 (expanded adult indication), Abrysvo (RSV vaccine), and the anticipated approval of Vupanorsen for hypercholesterolemia. The company is also advancing gene therapy for Duchenne muscular dystrophy and next-generation oncology assets. Despite near-term headwinds from patent expirations and COVID-related revenue normalization, Pfizer’s strong balance sheet and strategic business development efforts, including bolt-on acquisitions and partnerships, position it for long-term growth. The company’s conviction score of 70 reflects a solid pipeline and diversification, tempered by execution risks and competitive pressures.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on Vupanorsen (hypercholesterolemia)60% success
• H2 2026Phase 3 data readout for PF-06939926 (Duchenne muscular dystrophy)50% success
• H2 2026Phase 2b data for danuglipron (oral GLP-1 agonist for obesity)40% success